HomeLSTA • NASDAQ
add
Lisata Therapeutics Inc
Nakaraang pagsara
$2.58
Sakop ng araw
$2.43 - $2.59
Sakop ng taon
$1.87 - $4.20
Market cap
21.15M USD
Average na Volume
12.86K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | — | — |
Gastos sa pagpapatakbo | 5.85M | -11.42% |
Net na kita | -4.72M | 12.53% |
Net profit margin | — | — |
Kita sa bawat share | -0.55 | 15.38% |
EBITDA | -5.80M | 11.46% |
Aktuwal na % ng binabayarang buwis | 16.92% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 25.83M | -40.41% |
Kabuuang asset | 28.98M | -39.92% |
Kabuuang sagutin | 3.88M | -29.43% |
Kabuuang equity | 25.10M | — |
Natitirang share | 8.60M | — |
Presyo para makapag-book | 0.88 | — |
Return on assets | -45.69% | — |
Return on capital | -53.50% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -4.72M | 12.53% |
Cash mula sa mga operasyon | -5.40M | 23.13% |
Cash mula sa pag-invest | 9.43M | 46.54% |
Cash mula sa financing | -23.00K | 83.80% |
Net change in cash | 4.01M | 608.63% |
Malayang cash flow | -4.32M | 24.29% |
Tungkol
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
Itinatag
1980
Headquarters
Website
Mga Empleyado
26
